Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program
December 12 2017 - 9:23AM
Business Wire
An In-Depth Look at How Good Clinical Practices
Ensure Ethical Conduct of High Quality Research and the Safety of
Study Subjects
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM)
today released its latest Scientific Update for Smoke-Free
Products, a regular publication on its research efforts to develop
and assess a range of smoke-free alternatives to cigarettes. The
latest issue of the Scientific Update can be found at this
link.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171212005891/en/
Philip Morris International Releases
Latest Scientific Update for Smoke-Free Products on Clinical
Program (Photo: Business Wire)
This issue of the Scientific Update provides a closer look at
some of the principles and practices on which PMI’s scientific
assessment program is built. Director Medical Affairs Dr. Patrick
Picavet describes specific examples from PMI’s clinical program
that highlight the company’s commitment to the implementation of
best practices, transparent research and the well-being of clinical
trial participants.
Picavet stated, “The performance of clinical studies is a
complicated process. Strict implementation of Good Clinical
Practices is particularly important to assure the quality and
consistency of the research and to address unexpected events that
can occur during a study. These Practices are key to the validity
of data and the safety of study participants.”
Beyond recent events and publications, this issue also describes
PMI’s progress towards sharing all raw data from studies on IQOS in
part through the new data-sharing platform called INTERVALS.
Prof. Manuel Peitsch, PMI’s Chief Scientific Officer,
elaborates: “PMI is committed to openly sharing the research behind
our smoke-free products. That’s why we are using our latest
Scientific Update to explain the rigor behind our clinical program.
We are going further by gradually making the data and results from
the non-clinical and clinical program around our leading smoke-free
product, IQOS, available to the public by early 2018.”
PMI’s extensive research and assessment program is inspired by
the well-recognized practices of the pharmaceutical industry and in
line with the draft guidance of the U.S. FDA for Modified Risk
Tobacco Product (MRTP) Applications. PMI employs over 400
world-class scientists, engineers and experts who conduct rigorous
research, including laboratory and clinical studies, as well as
ground-breaking systems toxicology. The assessment program also
includes studies on actual product use and correct understanding of
product communications, as well as post-market research.
About Philip Morris International Inc. (“PMI”)
Philip Morris International Inc. (PMI) is a leading
international tobacco company, with six of the world's top 15
international brands and products sold in more than 180 markets. In
addition to the manufacture and sale of cigarettes,
including Marlboro, the number one global cigarette brand, and
other tobacco products, PMI is engaged in the development and
commercialization of reduced-risk products (RRPs). RRPs is the term
PMI uses to refer to products that present, are likely to present,
or have the potential to present less risk of harm to smokers who
switch to these products versus continued smoking. Through
multidisciplinary capabilities in product development,
state-of-the-art facilities, and industry-leading scientific
substantiation, PMI aims to provide an RRP portfolio that meets a
broad spectrum of adult smoker preferences and rigorous regulatory
requirements. For more information, see
our PMI and PMI Science websites.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171212005891/en/
Media enquiriesPhilip Morris International media officeT: +41
(0)58 242 4500E: media@pmi.com
Philip Morris (NYSE:PM)
Historical Stock Chart
From Apr 2024 to May 2024
Philip Morris (NYSE:PM)
Historical Stock Chart
From May 2023 to May 2024